Back to News
Market Impact: 0.35
Supernus Completes Merger With Indivior; Creates CNS-Focused Biopharma
Source: Nasdaq
M&A & RestructuringHealthcare & BiotechCompany Fundamentals
Supernus Pharmaceuticals and Indivior Pharmaceuticals completed their previously announced merger, creating a diversified, CNS-focused biopharmaceutical company. The combined company will operate as Supernus, Inc. and continue trading on Nasdaq under the ticker SUPN.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
INDV0.40
SUPN0.40
More News
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell-Lumentum Deal Puts Optical Networking at the Center of the AI Boom
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- Disney Plans Thousands of Layoffs Companywide
- AMD rides data center riches to ‘largest and most profitable’ quarter in history